Login / Signup

Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56 bright CD16 - subset.

Irene VenezianiClaudia AlicataAndrea PelosiNadine LandolinaBiancamaria RicciValentina D'OriaAnna FagottiGiovanni ScambiaLorenzo MorettaEnrico Maggi
Published in: Journal for immunotherapy of cancer (2022)
These data highlight the potential value of TLR8 in NK cells as a new target for immunotherapy in patients with cancer.
Keyphrases
  • nk cells
  • toll like receptor
  • nuclear factor
  • inflammatory response
  • immune response
  • electronic health record
  • cancer therapy
  • drug delivery
  • machine learning
  • data analysis
  • risk assessment